stockrow
Saturday 7 November 2026
Export ARCT’s income statement to Excel — free account
Arcturus Therapeutics Holdings Inc.
ARCT Healthcare Biotechnology
Arcturus Therapeutics Holdings Inc.’s revenue for fiscal 2025 (year ended December 2025) was $82.0 million, down 46.1% from fiscal 2024.
- Revenue
- +6.68%
- EPS
- +46.9%
- Free cash flow
- +59.9%
Quarter to September 2026, against a year earlier
10.35
0.99
+10.58%
Follow ARCT
Alert me
| Sep '26 From the 10-Q filed 5 Nov | Jun '26 | Mar '26 | Dec '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
12.76 | 6.50 | 4.01 | 2.05 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(56.39) | (9.59) | (11.29) | (10.35) | |
P/B ratio |
2.31 | 1.11 | 1.15 | 0.78 | |
Price to Tangible BV |
2.31 | 1.11 | 1.15 | 0.78 | |
EV/Sales |
9.18 | 2.56 | 1.53 | 0.15 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(4.48) | (1.03) | (1.43) | (0.17) | |
EV/FCF |
(4.49) | (1.03) | (1.43) | (0.17) | |
Quick Ratio |
6.56 | 5.76 | 6.19 | 6.50 | |
Current Ratio |
6.68 | 5.88 | 6.31 | 6.64 | |
Net Debt/EBITDA |
0.00 | 7.69 | 7.48 | 7.54 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.12 | 0.11 | 0.19 | 0.27 | |
Operating CF/Net income |
0.93 | 0.84 | 0.72 | 0.56 | |
Capex/Depreciation |
0.00 | 0.03 | 0.05 | 0.13 | |
Interest Coverage |
— | 14.04 | 14.97 | 20.56 | |
Research and Development Expense of Revenue |
92.90% | 591.92% | 1,044.49% | 340.07% | |
Selling, General and Administrative Expense of Revenue |
57.30% | 371.38% | 459.24% | 194.91% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
22.09% | 142.99% | 209.85% | 94.72% | |
Graham Net Nets |
0.37 | 0.76 | 0.74 | 1.10 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(22.50%) | (49.26%) | (36.40%) | (38.83%) | |
Free Cash Flow Yield |
(16.03%) | (38.10%) | (26.72%) | (44.38%) | |
Revenue per Share |
0.64 | 0.10 | 0.07 | 0.26 | |
Operating CF per Share |
(0.24) | (0.70) | (0.68) | (0.59) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.24) | (0.70) | (0.68) | (0.59) | |
Cash per Share |
6.50 | 6.74 | 7.44 | 8.43 | |
Shareholders Equity per Share |
5.93 | 6.04 | 6.73 | 7.81 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
5.93 | 6.04 | 6.73 | 7.81 | |
Free Cash Flow |
(6.96) | (19.89) | (19.41) | (16.14) | |
Working Capital |
161.05 | 163.63 | 182.51 | 205.07 | |
Capital Expenditures |
(0.05) | 0.02 | 0.03 | 0.09 | |
Net Current Asset Value |
142.81 | 144.66 | 162.83 | 184.28 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | (0.01) | (0.02) | (0.01) | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
4.60 | 9.51 | 7.96 | 4.77 | |
Average Payables |
5.63 | 7.52 | 5.14 | 5.71 | |
Average Assets |
248.83 | 266.79 | 288.60 | 307.61 | |
Average Common Equity |
196.64 | 201.43 | 212.56 | 227.48 |
Columns are period end dates · fundamentals updated 5 Nov 2026